Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

被引：8
|
作者：
Stein, Alexander
Binder, Mascha
Al-Batran, Salah-Eddin
Hinke, Axel
Waberer, Lisa
Goekkurt, Eray
Meyer, Tobias
Statovci, Donjete
Depenbusch, Reinhard
Riera-Knorrenschild, Jorge
Lorenzen, Sylvie
Ettrich, Thomas Jens
Doerfel, Steffen
Bokemeyer, Carsten
Hegewisch-Becker, Susanna
机构：
[1] Univ Hamburg Eppendorf, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] UCT Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[4] CCRC, Dusseldorf, Germany
[5] Krankenhaus Nordwest IKF, Frankfurt, Germany
[6] Univ Canc Ctr Hamburg, Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[7] AIO Studien GmbH, Berlin, Germany
[8] Onkodok GmbH, Dedicated Res Facil, Guetersloh, Germany
[9] Universitatsklinikum, Giessen, Germany
[10] Tech Univ Munich, Dept Internal Med Hematol Med Oncol 3, Klin Rechts Isar, Munich, Germany
[11] Ulm Univ Hosp, Ulm, Germany
[12] Onkozentrum Dresden, Dresden, Germany
[13] Hamatologisch Onkolog Praxis Eppendorf, Hamburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3561
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3561
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CHARTA: FOLFOX plus bevacizumab plus /- irinotecan in advanced colorectal cancer (CRC)-Final results of the randomized phase II trial of the AIO (KRK 0209).
    Schmoll, Hans-Joachim
    Garlipp, Benjamin
    Junghanss, Christian
    Leithaeuser, Malte
    Vogel, Arndt
    Schaefers, Michael
    Kaiser, Ulrich
    Hoeffkes, Heinz-Gert
    Florschuetz, Axel
    Ruessel, Joern
    Kanzler, Stephan
    Edelmann, Thomas
    Forstbauer, Helmut
    Goehler, Thomas
    Hannig, Carla
    Hildebrandt, Bert
    Steighardt, Joerg
    Meinert, Fabian Maximilian
    Cygon, Franziska
    Stein, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [22] Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC)
    Becerra, C.
    Salazar, R.
    Garcia-Carbonero, R.
    Thomas, A. L.
    Vazquez-Mazon, F.
    Cassidy, J.
    Maughan, T.
    Gallen, M.
    Iveson, T.
    Hixon, M.
    Gualberto, A.
    Yin, D.
    Bergsland, E. K.
    Li, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
    Martinelli, E.
    Martini, G.
    Troiani, T.
    Pietrantonio, F.
    Avallone, A.
    Normanno, N.
    Nappi, A.
    Maiello, E.
    Falcone, A.
    Santabarbara, G.
    Pinto, C.
    Santini, D.
    Ciardiello, D.
    Terminiello, M.
    Borrelli, C.
    Napolitano, S.
    Renato, D.
    Famiglietti, V.
    Esposito, L.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S409 - S410
  • [24] A Phase II Trial of FOLFOX6 and Cetuximab in the First-line Treatment of Patients With Metastatic Colorectal Cancer
    Boccia, Ralph V.
    Cosgriff, Thomas M.
    Headley, David L.
    Badarinath, Suprith
    Dakhil, Shaker R.
    CLINICAL COLORECTAL CANCER, 2010, 9 (02) : 102 - 107
  • [25] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Chen, E.
    Welch, S.
    Kryzanowska, M.
    Mackay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
  • [26] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Chen, E. X.
    Welch, S.
    Krzyzanowska, M.
    MacKay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] FOLFOX / Bevacizumab (Beva) plus /- Irinotecan in advanced colorectal cancer (CRC): A randomized phase II trial (AIO KRK 0209, CHARTA)
    Schmoll, H. J.
    Garlipp, B.
    Junghanss, C.
    Leithauser, M.
    Vogel, A.
    Schaefers, M.
    Kaiser, U.
    Hoeffkes, H. G.
    Florschuetz, A.
    Ruessel, J.
    Kanzler, S.
    Edelmann, T.
    Forstbauer, H.
    Goehler, T.
    Hannig, C.
    Hildebrandt, B.
    Steighardt, J.
    Meinert, F. M.
    Cygon, F.
    Stein, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Huyghe, Nicolas
    De Cuyper, Astrid
    Sinapi, Isabelle
    Vempalli, Fazulur Rehaman
    Rinchai, Darawan
    Beyaert, Simon
    Verstraelen, Eleonore
    Goffette, Pierre
    Ghaye, Benoit
    Gilet, Melanie
    Van Maanen, Aline
    Castella, Marie-Laure
    Mlecnik, Bernhard
    Carrasco, Javier
    Galon, Jerome
    Bedognetti, Davide
    Van den Eynde, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).
    Kasper, Stefan
    Goetze, Thorsten Oliver
    Stintzing, Sebastian
    Hofheinz, Ralf Dieter
    Sinn, Marianne
    Dechow, Tobias Nicolaas
    Ettrich, Thomas Jens
    Keitel, Verena
    Graeven, Ullrich
    von Weikersthal, Ludwig Fischer
    Kolov, Alexander
    Edelmann, Thomas
    Stein, Alexander
    Trarbach, Tanja
    Junge, Sabine
    Pauligk, Claudia
    Virchow, Isabel
    Siveke, Jens T.
    Al-Batran, Salah-Eddin
    Schuler, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial
    Verslype, Chris
    Hammel, Pascal
    Hidalgo, Manuel
    Macarulla, Teresa
    Garcia-Carbonero, Rocio
    Andre, Thierry
    Van den Eynde, Marc
    Saez, Berta Laquente
    Milella, Michele
    Raymond, Eric
    Faivre, Thea
    Milner, Alvin
    Tarabaric, Dolores
    Locatelli, Giuseppe
    von Richter, Oliver
    Laffranchi, Bernard
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345